IRONWOOD PHARMACEUTICALS INC 8-K

What Happened

• Ironwood Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 16, 2026 and filed an 8-K disclosing that shareholders approved an amendment to the Amended and Restated 2019 Equity Incentive Plan.
• The approved Plan Amendment increases the number of shares of the Company’s Class A common stock available for issuance under the plan by 10,000,000 shares. The Board had previously adopted the amendment subject to stockholder approval.

Key Details

• Annual Meeting date: June 16, 2026.
• Increase to equity plan: 10,000,000 additional shares of Class A common stock.
• Plan affected: Amended and Restated 2019 Equity Incentive Plan (terms summarized in the company’s Proxy Statement, pages 53–58).
• The Plan Amendment is attached to the 8-K as Exhibit 10.1.

Why It Matters

• This approval gives the company additional shares it can grant for employee, director or consultant equity awards, which can support hiring and retention programs.
• New share authorizations can dilute existing shareholders over time if granted and issued; investors should monitor future equity grants and total diluted share count.
• The filing does not disclose specific planned grants or financial impacts; review the referenced Proxy Statement and future filings for details on grant activity and dilution.